Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas
Key facts
- Who runs it
- Fayoum University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 66 people enrolled
- Started
- 10 Aug 2025
- Ended
- 13 Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- loteprednol etabonate 1% arm 1
- prednisolone acete 1%
- Record updated
- 27 March 2026
Who can take part
- Age
- 4 years to 21 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Any patient presenting with an active anterior chamber granuloma
- Patients must be treatment-naïve, having received no previous medical treatment for the current condition
- Willingness of the parent or legal guardian to provide written informed consent
Who cannot take part
- History of recurrent uveitis
- Active corneal infection or corneal ulcer
- Active inflammation clearly attributed to trauma, lens-induced causes, or underlying rheumatologic disease
- Pre-existing glaucoma or a baseline intraocular pressure greater than 21 mmHg
- Presence of a cataract
- Evidence of active posterior uveitis
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to compare the efficacy and safety of two different topical corticosteroids in 66 pediatric patients with active anterior chamber granuloma.
Read full original descriptionShow less
The main questions it aims to answer are:
* Does Loteprednol Etabonate 1% provide equivalent inflammation control and granuloma resolution compared to Prednisolone Acetate 1% over a 3-month period? * Does Loteprednol Etabonate 1% result in a lower frequency of steroid-related intraocular pressure (IOP) elevations than Prednisolone Acetate 1%? Researchers compared a group receiving Loteprednol Etabonate 1% four times daily to a group receiving Prednisolone Acetate 1% six times daily to see if Loteprednol could maintain comparable therapeutic effectiveness while offering a safer intraocular pressure profile.
Participants will Be randomized to receive either Loteprednol Etabonate 1% or Prednisolone Acetate 1% eye drops.
Follow a specific dosing schedule (4 times/day for Loteprednol or 6 times/day for Prednisolone).
Undergo a clinician-guided medication tapering schedule based on clinical response.
Attend follow-up assessments at day 1, 2 weeks, 1 month, and 3 months for eye examinations and pressure monitoring.
Be referred for surgical management if they do not demonstrate adequate clinical improvement after 4 weeks of therapy.
The 2 groups in the trial
- loteprednol etabonate 1% groupTreatment being tested
Participants in this group received loteprednol etabonate 1% eye drops administered four times daily. The treatment was followed by a clinician-guided tapering schedule based on the clinical improvement of anterior chamber activity and the reduction or clearance of the lesion as observed on slit-lamp examination.
Treatment: loteprednol etabonate 1% arm 1
- prednisolone acetate 1% groupExisting treatment, for comparison
Participants in this group received prednisolone acetate 1% eye drops administered six times daily. As this medication is a suspension, patients were instructed to shake the bottle before each instillation. Similar to the first group, doses were tapered by the treating clinician according to the patient's clinical response and reduction in SUN anterior chamber grading.
Treatment: prednisolone acete 1%
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas: A Randomized Study
- Record updated
- 27 March 2026